Retrospective analysis of bendamustine and rituximab use in indolent and mantle cell non-Hodgkin lymphoma based on initial starting dose

The initial dose of bendamustine, an alkylating agent used in treating indolent lymphoma (iNHL) and mantle cell lymphoma, is variable in clinical practice. 134 patients treated with bendamustine and rituximab were evaluated for starting dosage, patient characteristics, toxicities, and clinical outco...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Leuk Lymphoma
Hlavní autoři: Bond, David A., Huang, Ying, Ruppert, Amy S., Walker, Alison R., Dotson, Emily K., Roddy, Julianna, Blum, Kristie A., Christian, Beth A.
Médium: Artigo
Jazyk:Inglês
Vydáno: 2016
Témata:
Article
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC5499523/
https://ncbi.nlm.nih.gov/pubmed/27838951
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/10428194.2016.1253835
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky